ClinicalTrials.gg
CompletedNCT01436526Updated Apr 22, 2015Results posted

Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

A Phase 1 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban (Xarelto, BAY59-7939) in Therapeutic Equivalency, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-22.

Sponsored by Bayer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The drug investigated in this study is Rivaroxaban, a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery.

The purpose of this study is to establish bioequivalence of 2 immediate-release tablet treatments with Rivaroxaban: 2*5 mg tablets and 1*10 mg tablet will be given to healthy volunteers under fasting conditions; they will be administered as single oral doses in 2 periods. Both periods will be separated by a 7-day washout phase. Thus, the bioequivalence represents the primary study objective. As a secondary objective, this treatment will be assessed in terms of safety and tolerability.

Bioequivalence will be evaluated and verified on the basis of pharmacokinetic data. Blood samples of the volunteers will be taken at specific points in time; these samples will be analyzed using various statistical methods to establish pharmacokinetic characteristics required to compare the 2 treatments. The planned treatments with Rivaroxaban will be considered bioequivalent if specific criteria defined in the study protocol are met.

The study will be conducted in one center in Germany. 28 subjects meeting the inclusion criteria will participate. They will be treated according to a single-dose, randomized, 2-way cross-over, non-placebo-controlled design.

02

Conditions studied

  • Therapeutic Equivalency

Keywords

  • Bioequivalence
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects
  • 18 to 45 years of age
  • (BMI) between 18 and 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Conspicuous findings (medical history, screening)
  • History of relevant diseases (internal organs, central nervous system or other organs)
  • Medical disorder, condition or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator or the sponsor
  • Febrile illness within 1 week before the start of the study
  • History of severe allergies, non-allergic drug reactions, or multiple drug allergies
  • to the drug, the control agent and/or to inactive constituents
  • Known coagulation disorders, known disorders with increased bleeding risk, known sensitivity to common causes of bleeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg

    Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg

    Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

Interventions

  • Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)

  • Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation

    The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (AUC is defined as area under the concentration vs. time curve from zero to infinity after single (first) dose).

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

  2. Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tn)] Incl. Bioequivalence (BE) Evaluation

    The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; \[AUC (0-tn)\] is defined as AUC from time 0 to the last data point above the Lower Limit of Quantification.

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

  3. Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax) Incl. Bioequivalence (BE) Evaluation

    Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve Divided by Dose Per kg Body Weight (AUCnorm)

    The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUCnorm is defined as AUC divided by dose per kg body weight.

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

  2. Maximum Observed Drug Concentration in Plasma After Single Dose Administration Divided by Dose Per kg Body Weight (Cmax, Norm)

    Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; Cmax,norm is defined as Cmax divided by dose (mg) per kg body weight.

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

  3. Mean Residence Time (MRT)

    The mean residence time is the average time that the molecules introduced into the body stay in the body.

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

  4. Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)

    Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

  5. Half-life Associated With the Terminal Slope (t½)

    Half-life refers to the elimination of the drug, i.e. the time it takes for the blood plasma concentration to reach half the concentration in the terminal phase of elimination.

    Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration

07

Results

Posted Dec 22, 2011

Participant flow

All participants (part.) recruited by CRS Clinical-Research-Services Moenchengladbach GmbH, Hindenburgstrasse 304 - 306, 41061 Moenchengladbach, Germany. 28 part. were planned to be enrolled.

Period 1
Participant flow — Period 1
MilestoneRivaroxaban (Xarelto, BAY59-7939) First 2*5 mg, Then 1*10 mgRivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mg
Started1414
Participants received treatment1414
Completed1414
Not completed00
Period 2
Participant flow — Period 2
MilestoneRivaroxaban (Xarelto, BAY59-7939) First 2*5 mg, Then 1*10 mgRivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mg
Started1313
Participants received treatment1313
Completed1313
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (AUC is defined as area under the concentration vs. time curve from zero to infinity after single (first) dose).

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Geometric mean · µg*hr/L
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation
µg*hr/LRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation1374 ± 29.31268 ± 30.7
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg vs Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg · ANOVA · p = 0.0438 · Ls-mean ratio, percent: 108.35 · 90% CI 101.59 to 115.57
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tn)] Incl. Bioequivalence (BE) Evaluation

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; \[AUC (0-tn)\] is defined as AUC from time 0 to the last data point above the Lower Limit of Quantification.

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Geometric mean · µg*hr/L
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tn)] Incl. Bioequivalence (BE) Evaluation
µg*hr/LRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tn)] Incl. Bioequivalence (BE) Evaluation1354 ± 29.81252 ± 31.6
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg vs Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg · ANOVA · p = 0.0514 · Ls-mean ratio, percent: 108.19 · 90% CI 101.31 to 115.54
PrimaryMaximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax) Incl. Bioequivalence (BE) Evaluation

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Geometric mean · µg/L
Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax) Incl. Bioequivalence (BE) Evaluation
µg/LRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax) Incl. Bioequivalence (BE) Evaluation179.8 ± 31.1161.1 ± 38.7
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg vs Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg · ANOVA · p = 0.0685 · Ls-mean ratio, percent: 111.64 · 90% CI 101.14 to 123.23
SecondaryArea Under the Plasma Concentration Versus Time Curve Divided by Dose Per kg Body Weight (AUCnorm)

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUCnorm is defined as AUC divided by dose per kg body weight.

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Geometric mean · kg*hr/L
Area Under the Plasma Concentration Versus Time Curve Divided by Dose Per kg Body Weight (AUCnorm)
kg*hr/LRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Area Under the Plasma Concentration Versus Time Curve Divided by Dose Per kg Body Weight (AUCnorm)10.79 ± 33.09.957 ± 36.4
SecondaryMaximum Observed Drug Concentration in Plasma After Single Dose Administration Divided by Dose Per kg Body Weight (Cmax, Norm)

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; Cmax,norm is defined as Cmax divided by dose (mg) per kg body weight.

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Geometric mean · kg/L
Maximum Observed Drug Concentration in Plasma After Single Dose Administration Divided by Dose Per kg Body Weight (Cmax, Norm)
kg/LRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Maximum Observed Drug Concentration in Plasma After Single Dose Administration Divided by Dose Per kg Body Weight (Cmax, Norm)1.412 ± 35.31.265 ± 46.0
SecondaryMean Residence Time (MRT)

The mean residence time is the average time that the molecules introduced into the body stay in the body.

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Geometric mean · hr
Mean Residence Time (MRT)
hrRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Mean Residence Time (MRT)8.874 ± 22.09.284 ± 28.2
SecondaryTime to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Median · hr
Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)
hrRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)2.50 (0.75 to 3.00)2.50 (0.75 to 4.00)
SecondaryHalf-life Associated With the Terminal Slope (t½)

Half-life refers to the elimination of the drug, i.e. the time it takes for the blood plasma concentration to reach half the concentration in the terminal phase of elimination.

Time frame:
0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Reported as:
Geometric mean · hr
Half-life Associated With the Terminal Slope (t½)
hrRivaroxaban (Xarelto, BAY59-7939) 2*5 mgRivaroxaban (Xarelto, BAY59-7939) 1*10 mg
Half-life Associated With the Terminal Slope (t½)8.932 ± 48.68.721 ± 55.7

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban 2*5 mg (Xarelto, BAY59-7939)—0/27 (0%)6/27 (22.2%)
Rivaroxaban 1*10 mg (Xarelto, BAY59-7939)—0/27 (0%)6/27 (22.2%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRivaroxaban 2*5 mg (Xarelto, BAY59-7939)Rivaroxaban 1*10 mg (Xarelto, BAY59-7939)
Glutamate dehydrogenase increasedInvestigations2/270/27
Sinus bradycardiaCardiac disorders1/271/27
ConstipationGastrointestinal disorders0/271/27
DiarrhoeaGastrointestinal disorders0/271/27
DyspepsiaGastrointestinal disorders0/271/27
FatigueGeneral disorders0/271/27
Injection site haematomaGeneral disorders0/271/27
ContusionInjury, poisoning and procedural complications1/270/27
Alanine aminotransferase increasedInvestigations1/270/27
Aspartate aminotransferase increasedInvestigations1/270/27

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rivaroxaban (Xarelto, BAY59-7939) First 2*5 mg , Then 1*10 mgRivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mgTotal
Mean31.6 ± 5.831.3 ± 10.531.4 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (Xarelto, BAY59-7939) First 2*5 mg , Then 1*10 mgRivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mgTotal
Female000
Male141428
08

Study locations

1 site
  • Mönchengladbach, Nordrhein-Westfalen 41061, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2011
First posted
Sep 19, 2011
Start
Aug 2009
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Dec 22, 2011
Last update
Apr 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01436526
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Aug 2009
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Dec 22, 2011
Last update
Apr 22, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion